Current Cardiovascular Risk Reports

, Volume 6, Issue 2, pp 146–154 | Cite as

Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids

Novel and Emerging Risk Factors (N Wong and C Lewis, Section Editors)

Abstract

Lipids and their metabolites are now known to play essential roles in not only cardiovascular health and disease, but numerous other inflammatory processes as well. A multitude of diseases are being rigorously studied in the context of lipids and their metabolites. Dementias, rheumatologic and dermatologic diseases, neurologic repair, and proper neural development of the fetus and newborn child are just a few. The rapidly advancing fields of Lipidomics and more recently Signalolipidomics are reshaping our understanding of and approach to the mechanisms that lead to health and illness. In order for clinicians to become comfortable in this incontrovertibly relevant realm, they must develop a firm grasp of the fundamentals of lipids and their complex metabolism. As a consequence of the very high background intake of linoleic acid (LA) in the western world, alpha linolenic acid (ALA) cannot be efficiently and adequately converted into eicosapentaenoic and docosahexaenoic Acids (EPA and DHA) as well as their derivatives, all of which are fats known to augment health. Thus, EPA and DHA must be consumed in order for us to enjoy their myriad health benefits. In this review, EPA and DHA of the omega-3 family, and arachidonic acid (AA) of the omega-6 family, as well as their varied and oftentimes competing metabolites, are explored. Their nomenclature is explained and the integral roles they play in cardiovascular health and disease are emphasized.

Keywords

Fatty acids Omega-3 fatty acids Omega-6 fatty acids Polyunsaturated fats Prostanoids Eicosanoids Docosanoids Prostaglandins Prostacyclins Leukotrienes Thromboxanes Resolvins Protectins Eicosapentaenoic acid (EPA) Docosahexaenoic acid (DHA) Alpha linolenic acid (ALA) Linoleic acid (LA) Phospholipids Triglycerides (TG) Inflammation Anti-inflammatory Anti-oxidant Anti-thrombotic 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid, signalolipidomics in nutrition; significance in aging, neuroinflamation, macular degeneration, alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31:321–51. This review is an essential read for practitioners searching for a more in-depth view of this subject matter.PubMedCrossRefGoogle Scholar
  2. 2.
    • McMurry J: Biomolecules: Lipids. In Organic Chemistry 7e. Edited by Mary Finch. Brooks/Cole Cengage Learning; 2010;1:060–93. This review is an excellent summation of the relevant issues in this arena.Google Scholar
  3. 3.
    Guschina LA, Harwood JL. Lipids and lipid metabolism in eukaryotic algae. Prog Lipid Res. 2006;45:160–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Hu FB, Bronner LL, Willett WC, et al. Fish and Omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Lisa MN, Culiner J, Cunningham-Rundles S. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr. 2011;141:207–13.CrossRefGoogle Scholar
  7. 7.
    Duffy EM, Meenagh GK, McMillan SA, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol. 2004;31:1551–6.PubMedGoogle Scholar
  8. 8.
    Kobayashi N, Barnard J, Henning SM, et al. Effect of altering omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006;12(15):4662–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Hamazaki K, Terashima Y, Itomura M, et al. Docosahexaenoic acid is an independent predictor of all-cause mortality in hemodialysis patients. Am J Nephrol. 2011;33:105–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Wall R, Ross RP, Fitzgerald GF, et al. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010;68(5):280–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Egert S, Stehle P. Impact of nS3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care. 2011;14:121–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Oya J, Nakagami T, Sasak S. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. Eur J Clin Nutr. 2010;64:1179–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Simopoulos AP. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med. 2010;235:785–95.CrossRefGoogle Scholar
  14. 14.
    Kenchegowda S, Bazan HE. Significance of lipid mediators in corneal injury and repair. J Lipid Res. 2010;51:879–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Holub BJ. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostagl Leuk EFAs. 2009;81:199–204.CrossRefGoogle Scholar
  16. 16.
    Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol. 2000;11:3–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Clarke SD. Polyunsaturated regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr. 2001;131:1129–32.PubMedGoogle Scholar
  18. 18.
    Jump DB, Clarke SD. Regulation of gene expression by dietary fat. Annu Rev Nutr. 1999;19:63–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(suppl):27i–37.PubMedCrossRefGoogle Scholar
  20. 20.
    Mehra R. Global public health problem of sudden cardiac death. J Electrocardiol. 2007;40(6 Suppl):S118–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain omega-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain omega-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Am J Clin Nutr. 2000;71(sup):208S–12.PubMedGoogle Scholar
  23. 23.
    Leaf A. Plasma non-esterified fatty acid concentration as a risk factor for sudden cardiac death: the Paris prospective study. Circulation. 2001;104:744–55.PubMedGoogle Scholar
  24. 24.
    Kang JX, Leaf A. Prevention and termination of beta-adrenergic agonist-induced arrhythmias by free fatty acids in neonatal cardiac myocytes. Biochem Biophys Res Commun. 1995;208:629–36.PubMedCrossRefGoogle Scholar
  25. 25.
    Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110:368–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2004;7:131–6.CrossRefGoogle Scholar
  27. 27.
    Mas E, Woodman RJ, Burke V. The omega-3 fatty acids EPA and DHA decrease plasma F 2 -isoprostanes: Results from two placebo-controlled interventions. Free Radic Res. 2010;44(9):983–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Murakami M. Lipid mediators in life science. Exp Anim. 2011;609(1):7–20.CrossRefGoogle Scholar
  29. 29.
    Cawood AL, Ding R, Napper FL, et al. Long chain omega-3 fatty acids enter advanced atherosclerotic plaques and are associated with decreased inflammation and decreased inflammatory gene expression. Atherosclerosis. 2006;7(suppl):160.Google Scholar
  30. 30.
    Calder PC, Albers R, Antoine JM. Inflammatory disease processes and interactions with nutrition. Brit J Nutr. 2009;101:S1–45.PubMedGoogle Scholar
  31. 31.
    Calder, P. OCEAN TrialGoogle Scholar
  32. 32.
    Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein Cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45:1594–607.PubMedCrossRefGoogle Scholar
  34. 34.
    Harris WS, von Schacky C. The omega-3 index: a new risk factor for sudden cardiac death? Prev Med. 2004;39:212–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Mori T, Berlin L. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Rinaldo-Matthis A, Haeggström JZ. Structures and mechanisms of enzymes in the leukotriene cascade. Biochimie. 2010;92:676–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in vascular diseases. Circ J. 2010;74:836–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Capone ML, Tacconelli S, Rodriguez LG, et al. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacology Reports. 2010;62:530–5.Google Scholar
  39. 39.
    Ruan CH, So SP, Ruan KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease. Life Sci. 2011;88:24–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Flammer AJ, Luscher TF. Human endothelial dysfunction: EDRFs. Eur J Physiol. 2010;459:1005–13.CrossRefGoogle Scholar
  41. 41.
    Bellien J, Joannides R, Richard V, et al. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: A promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther. 2011;131:1–17.PubMedCrossRefGoogle Scholar
  42. 42.
    Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006;6:414–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Hersberger M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin Chem Lab Med. 2010;48:1063–73.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Calder PC. Fatty acids and inflammation: The cutting edge between food and pharma. European J Pharmacol. 2011;xxx-xxx. This review is an excellent summation of the relevant issues in this arena.Google Scholar
  45. 45.
    Chen P, Fenet B, Michaud S, et al. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 2009;583:3478–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Women’s Preventive Cardiology, Christine E. Lynn Women’s Health and Wellness InstituteBoca Raton Regional HospitalBoca RatonUSA
  2. 2.University of MiamiMiller School of MedicineMiamiUSA

Personalised recommendations